Harpoon Therapeutics Key Executives
This section highlights Harpoon Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Harpoon Therapeutics
(Showing 0 of )
Harpoon Therapeutics Earnings
This section highlights Harpoon Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Harpoon Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $31.91M | $23.65M | $17.44M | $5.78M | $4.75M |
| Cost of Revenue | $3.10M | $2.65M | $- | $- | $- |
| Gross Profit | $28.82M | $21.01M | $17.44M | $5.78M | $4.75M |
| Gross Profit Ratio | 90.30% | 88.80% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $81.39M | $72.12M | $52.56M | $41.59M | $26.37M |
| General and Administrative Expenses | $18.85M | $18.33M | $16.21M | $22.39M | $6.11M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $18.85M | $18.33M | $16.21M | $22.39M | $6.11M |
| Other Expenses | $-182.00K | $-210.00K | $-26.00K | $-42.00K | $-37.00K |
| Operating Expenses | $100.24M | $90.45M | $68.78M | $63.98M | $32.47M |
| Cost and Expenses | $100.24M | $90.45M | $68.78M | $63.98M | $32.47M |
| Interest Income | $776.00K | $240.00K | $1.45M | $2.68M | $395.00K |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $2.36M | $102.10M | $2.08M | $900.00K | $644.00K |
| EBITDA | $-65.97M | $-14.65M | $-49.25M | $-58.21M | $-27.37M |
| EBITDA Ratio | -207.00% | -61.95% | -294.26% | -1007.55% | -576.13% |
| Operating Income | $-68.33M | $-116.75M | $-51.33M | $-58.21M | $-27.72M |
| Operating Income Ratio | -214.08% | -493.58% | -294.26% | -1007.55% | -583.66% |
| Total Other Income Expenses Net | $594.00K | $30.00K | $1.42M | $2.63M | $358.00K |
| Income Before Tax | $-67.73M | $-116.72M | $-49.91M | $-55.57M | $-27.37M |
| Income Before Tax Ratio | -212.22% | -493.45% | -286.10% | -961.95% | -576.13% |
| Income Tax Expense | $-594.00K | $49.71M | $-3.53M | $-3.58M | $358.00K |
| Net Income | $-67.14M | $-166.44M | $-46.38M | $-52.00M | $-27.37M |
| Net Income Ratio | -210.36% | -703.62% | -265.86% | -900.05% | -576.13% |
| EPS | $-20.24 | $-51.57 | $-18.52 | $-23.91 | $-11.45 |
| EPS Diluted | $-20.24 | $-51.57 | $-18.52 | $-23.91 | $-11.45 |
| Weighted Average Shares Outstanding | 3.32M | 3.23M | 2.50M | 2.17M | 2.39M |
| Weighted Average Shares Outstanding Diluted | 3.32M | 3.23M | 2.50M | 2.17M | 2.39M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.45M | $20.22M | $8.58M | $4.09M | $13.62M | $8.30M | $5.91M | $4.33M | $4.48M | $5.84M | $9.01M | $7.49M | $3.89M | $2.76M | $3.30M | $2.23M | $1.42M | $1.06M | $1.06M | $1.06M |
| Cost of Revenue | $236.00K | $568.00K | $1.10M | $910.00K | $706.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $4.21M | $19.65M | $7.48M | $3.18M | $12.91M | $8.30M | $5.91M | $4.33M | $4.48M | $5.84M | $9.01M | $7.49M | $3.89M | $2.76M | $3.30M | $2.23M | $1.42M | $1.06M | $1.06M | $1.06M |
| Gross Profit Ratio | 94.70% | 97.20% | 87.10% | 77.70% | 94.80% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $12.32M | $12.20M | $15.16M | $18.95M | $20.98M | $20.65M | $20.82M | $20.66M | $16.97M | $18.27M | $16.22M | $15.06M | $13.06M | $11.92M | $12.52M | $12.71M | $9.53M | $9.97M | $9.38M | $8.72M |
| General and Administrative Expenses | $4.26M | $3.80M | $4.18M | $3.85M | $4.53M | $5.06M | $5.40M | $5.20M | $4.19M | $4.33M | $4.60M | $3.92M | $4.43M | $3.94M | $3.91M | $4.33M | $8.49M | $3.73M | $5.83M | $2.21M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.26M | $3.80M | $4.18M | $3.85M | $4.53M | $5.06M | $5.40M | $5.20M | $4.19M | $4.33M | $4.60M | $3.92M | $4.43M | $3.94M | $3.91M | $4.33M | $8.49M | $3.73M | $5.83M | $2.21M |
| Other Expenses | $11.90M | $-488.00K | $-860.00K | $-50.00K | $-40.00K | $-44.00K | $-48.00K | $-47.00K | $-55.00K | $-58.00K | $-51.00K | $-11.00K | $-14.00K | $- | $-1.00K | $4.00K | $-26.00K | $-15.00K | $40.00K | $-8.00K |
| Operating Expenses | $16.59M | $16.00M | $19.35M | $22.80M | $25.51M | $25.71M | $26.22M | $25.87M | $21.16M | $22.61M | $20.82M | $18.99M | $17.48M | $15.87M | $16.43M | $17.04M | $18.03M | $13.71M | $15.21M | $10.93M |
| Cost and Expenses | $16.59M | $16.00M | $19.35M | $22.80M | $25.51M | $25.71M | $26.22M | $25.87M | $21.16M | $22.61M | $20.82M | $18.99M | $17.48M | $15.87M | $16.43M | $17.04M | $18.03M | $13.71M | $15.21M | $10.93M |
| Interest Income | $480.00K | $615.00K | $425.00K | $343.00K | $289.00K | $104.00K | $40.00K | $36.00K | $48.00K | $62.00K | $94.00K | $151.00K | $299.00K | $415.00K | $584.00K | $532.00K | $727.00K | $840.00K | $532.00K | $148.00K |
| Interest Expense | $2.05M | $1.56M | $138.00K | $- | $289.00K | $104.00K | $40.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $236.00K | $370.00K | $227.00K | $678.00K | $527.00K | $548.00K | $604.00K | $558.00K | $534.00K | $549.00K | $549.00K | $537.00K | $530.00K | $512.00K | $503.00K | $500.00K | $-196.00K | $299.00K | $297.00K | $197.00K |
| EBITDA | $480.00K | $2.49M | $-10.77M | $-18.71M | $-11.18M | $-16.69M | $-19.71M | $-20.98M | $-16.14M | $-16.22M | $-11.16M | $-11.50M | $-13.06M | $-12.60M | $-12.63M | $-14.80M | $-16.61M | $-12.64M | $-13.85M | $-9.73M |
| EBITDA Ratio | 11.00% | 12.00% | -125.00% | -457.62% | -83.44% | -203.10% | -333.71% | -485.16% | -359.97% | -277.82% | 429.55% | -153.46% | -335.53% | -456.01% | -383.14% | -662.71% | -1172.12% | -1189.28% | -1303.29% | -915.24% |
| Operating Income | $-12.14M | $2.49M | $-10.77M | $-18.71M | $-11.89M | $-17.41M | $-20.31M | $-21.54M | $-16.68M | $-16.77M | $-61.77M | $-11.50M | $-13.59M | $-13.11M | $-13.13M | $-14.80M | $-16.61M | $-12.64M | $-14.15M | $-9.87M |
| Operating Income Ratio | -272.91% | 12.33% | -125.42% | -457.62% | -87.31% | -209.70% | -343.94% | -498.06% | -371.88% | -287.22% | -685.77% | -153.46% | -349.14% | -474.55% | -398.39% | -662.71% | -1172.12% | -1189.28% | -1331.23% | -928.41% |
| Total Other Income Expenses Net | $10.34M | $-1.43M | $-573.00K | $292.00K | $249.00K | $60.00K | $-8.00K | $-10.00K | $-7.00K | $4.00K | $43.00K | $140.00K | $285.00K | $415.00K | $583.00K | $536.00K | $701.00K | $825.00K | $572.00K | $142.00K |
| Income Before Tax | $-1.80M | $1.06M | $-11.34M | $-18.42M | $-11.64M | $-17.35M | $-20.32M | $-21.55M | $-16.68M | $-16.76M | $-61.72M | $-11.36M | $-13.31M | $-12.69M | $-12.55M | $-14.27M | $-15.91M | $-11.82M | $-13.58M | $-9.73M |
| Income Before Tax Ratio | -40.51% | 5.24% | -132.10% | -450.48% | -85.48% | -208.97% | -344.07% | -498.31% | -372.03% | -287.15% | -685.29% | -151.59% | -341.82% | -459.52% | -380.71% | -638.72% | -1122.65% | -1111.67% | -1277.42% | -915.24% |
| Income Tax Expense | $-236.00K | $1.07M | $711.00K | $-345.00K | $-249.00K | $-60.00K | $8.00K | $-36.00K | $-48.00K | $-62.00K | $49.86M | $-688.00K | $-299.00K | $- | $-584.00K | $-1.03M | $-531.00K | $-1.14M | $-532.00K | $-205.00K |
| Net Income | $-1.80M | $1.06M | $-12.05M | $-18.07M | $-11.39M | $-17.29M | $-20.33M | $-21.55M | $-16.68M | $-16.76M | $-61.72M | $-11.36M | $-13.31M | $-12.69M | $-12.55M | $-14.27M | $-15.91M | $-11.82M | $-13.58M | $-9.73M |
| Net Income Ratio | -40.51% | 5.25% | -140.38% | -442.04% | -83.65% | -208.25% | -344.21% | -498.31% | -372.03% | -287.15% | -685.29% | -151.59% | -341.82% | -459.52% | -380.71% | -638.72% | -1122.65% | -1111.67% | -1277.42% | -915.24% |
| EPS | $-0.46 | $0.30 | $-3.26 | $-5.37 | $-3.45 | $-5.23 | $-6.18 | $-6.60 | $-5.10 | $-5.20 | $-19.50 | $-4.50 | $-5.30 | $-5.10 | $-5.10 | $-5.80 | $-6.50 | $-4.90 | $-9.20 | $-4.07 |
| EPS Diluted | $-0.46 | $0.30 | $-3.26 | $-5.37 | $-3.45 | $-5.23 | $-6.18 | $-6.60 | $-5.10 | $-5.20 | $-19.50 | $-4.50 | $-5.30 | $-5.10 | $-5.10 | $-5.80 | $-6.50 | $-4.90 | $-9.20 | $-4.07 |
| Weighted Average Shares Outstanding | 3.95M | 3.77M | 3.70M | 3.37M | 3.31M | 3.30M | 3.29M | 3.27M | 3.26M | 3.25M | 3.16M | 2.53M | 2.51M | 2.50M | 2.48M | 2.46M | 2.45M | 2.43M | 1.48M | 2.39M |
| Weighted Average Shares Outstanding Diluted | 3.95M | 3.80M | 3.70M | 3.37M | 3.31M | 3.30M | 3.29M | 3.27M | 3.26M | 3.25M | 3.16M | 2.53M | 2.51M | 2.50M | 2.48M | 2.46M | 2.45M | 2.43M | 1.48M | 2.39M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $51.61M | $44.69M | $21.17M | $155.13M | $89.49M |
| Short Term Investments | $1.50M | $90.41M | $104.86M | $59.34M | $- |
| Cash and Short Term Investments | $53.11M | $135.10M | $149.98M | $155.13M | $89.49M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $1.61M | $2.60M | $3.72M | $2.54M | $730.00K |
| Total Current Assets | $54.73M | $137.69M | $129.75M | $150.62M | $90.22M |
| Property Plant Equipment Net | $18.09M | $15.38M | $16.77M | $18.40M | $3.00M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $673.00K | $1.52M | $23.95M | $7.06M | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $238.00K | $860.00K | $1.12M | $533.00K | $9.36M |
| Total Non-Current Assets | $19.00M | $17.76M | $41.84M | $25.99M | $12.36M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $73.73M | $155.45M | $171.59M | $176.60M | $102.58M |
| Account Payables | $4.71M | $2.67M | $1.57M | $2.59M | $4.36M |
| Short Term Debt | $2.42M | $1.65M | $1.20M | $1.22M | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $30.94M | $37.46M | $31.30M | $11.21M | $4.25M |
| Other Current Liabilities | $14.36M | $17.36M | $13.85M | $7.50M | $3.34M |
| Total Current Liabilities | $52.43M | $59.14M | $47.92M | $22.51M | $11.95M |
| Long Term Debt | $13.58M | $10.54M | $12.31M | $13.73M | $- |
| Deferred Revenue Non-Current | $2.31M | $27.70M | $57.52M | $46.14M | $7.79M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $136.32M |
| Total Non-Current Liabilities | $15.90M | $38.24M | $69.83M | $59.87M | $144.11M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $68.33M | $97.38M | $117.75M | $82.38M | $156.06M |
| Preferred Stock | $- | $155.45M | $171.59M | $176.60M | $129.58M |
| Common Stock | $4.00K | $4.00K | $3.00K | $3.00K | $1.00K |
| Retained Earnings | $-352.52M | $-284.79M | $-168.07M | $-118.16M | $-62.59M |
| Accumulated Other Comprehensive Income Loss | $-3.00K | $-47.00K | $3.00K | $41.00K | $-1.01M |
| Other Total Stockholders Equity | $357.92M | $342.90M | $221.90M | $212.34M | $-120.47M |
| Total Stockholders Equity | $5.40M | $58.07M | $53.84M | $94.22M | $-53.48M |
| Total Equity | $5.40M | $58.07M | $53.84M | $94.22M | $-53.48M |
| Total Liabilities and Stockholders Equity | $73.73M | $155.45M | $171.59M | $176.60M | $102.58M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $73.73M | $155.45M | $171.59M | $176.60M | $102.58M |
| Total Investments | $1.50M | $91.93M | $128.81M | $66.39M | $- |
| Total Debt | $16.01M | $12.19M | $13.52M | $14.94M | $- |
| Net Debt | $-35.61M | $-32.50M | $-7.66M | $-140.19M | $-89.49M |
Balance Sheet Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $17.74M | $32.80M | $61.38M | $51.61M | $50.37M | $68.57M | $50.74M | $44.69M | $42.99M | $77.41M | $71.33M | $21.17M | $22.65M | $34.74M | $36.17M | $155.13M | $56.76M | $133.88M | $95.93M | $89.49M |
| Short Term Investments | $13.87M | $12.76M | $- | $1.50M | $15.73M | $21.59M | $61.73M | $90.41M | $108.39M | $93.60M | $158.08M | $104.86M | $132.16M | $136.88M | $86.93M | $59.34M | $64.46M | $81.79M | $42.65M | $- |
| Cash and Short Term Investments | $31.61M | $45.55M | $61.38M | $53.11M | $66.10M | $90.15M | $112.47M | $135.10M | $151.39M | $171.02M | $229.41M | $149.98M | $154.81M | $171.62M | $123.10M | $155.13M | $121.23M | $133.88M | $138.57M | $89.49M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $2.69M | $3.51M | $2.48M | $1.61M | $3.05M | $3.88M | $4.48M | $2.60M | $4.80M | $4.66M | $4.87M | $3.72M | $2.92M | $3.16M | $5.60M | $2.54M | $1.76M | $3.44M | $2.08M | $730.00K |
| Total Current Assets | $34.30M | $49.07M | $63.86M | $54.73M | $69.15M | $94.04M | $116.94M | $137.69M | $156.19M | $175.68M | $234.28M | $129.75M | $157.72M | $174.78M | $128.70M | $150.62M | $122.99M | $137.32M | $140.65M | $90.22M |
| Property Plant Equipment Net | $12.38M | $12.97M | $16.17M | $18.09M | $13.54M | $14.04M | $14.69M | $15.38M | $14.94M | $15.56M | $16.24M | $16.77M | $17.20M | $17.64M | $17.89M | $18.40M | $18.88M | $19.23M | $13.62M | $3.00M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $206.00K | $673.00K | $673.00K | $673.00K | $673.00K | $- | $- | $1.52M | $2.84M | $4.19M | $9.99M | $23.95M | $7.51M | $3.83M | $15.14M | $7.06M | $- | $- | $8.98M | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $692.00K | $492.00K | $107.00K | $238.00K | $138.00K | $869.00K | $813.00K | $860.00K | $700.00K | $747.00K | $805.00K | $1.12M | $888.00K | $868.00K | $763.00K | $533.00K | $521.00K | $467.00K | $3.68M | $9.36M |
| Total Non-Current Assets | $13.28M | $14.13M | $16.95M | $19.00M | $14.35M | $14.91M | $15.50M | $17.76M | $18.48M | $20.50M | $27.04M | $41.84M | $25.60M | $22.34M | $33.80M | $25.99M | $19.40M | $19.69M | $26.28M | $12.36M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $47.58M | $63.20M | $80.81M | $73.73M | $83.50M | $108.95M | $132.45M | $155.45M | $174.67M | $196.18M | $261.32M | $171.59M | $183.32M | $197.12M | $162.50M | $176.60M | $142.39M | $157.02M | $166.93M | $102.58M |
| Account Payables | $3.44M | $3.63M | $4.00M | $4.71M | $2.64M | $2.79M | $4.19M | $2.67M | $1.60M | $2.00M | $2.64M | $1.57M | $1.78M | $1.59M | $1.54M | $2.59M | $3.90M | $4.52M | $3.41M | $4.36M |
| Short Term Debt | $2.97M | $2.88M | $2.79M | $2.42M | $1.83M | $1.77M | $1.71M | $1.65M | $1.59M | $1.54M | $1.48M | $1.20M | $1.36M | $1.31M | $1.26M | $1.22M | $987.00K | $862.00K | $572.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $4.45M | $22.36M | $30.94M | $33.96M | $36.50M | $36.88M | $37.46M | $38.15M | $34.82M | $30.84M | $31.30M | $31.64M | $27.09M | $13.87M | $11.21M | $4.08M | $4.25M | $4.25M | $4.25M |
| Other Current Liabilities | $11.70M | $14.38M | $15.03M | $14.36M | $15.63M | $17.16M | $15.81M | $17.36M | $14.04M | $16.34M | $63.20M | $13.85M | $10.44M | $9.06M | $7.13M | $7.50M | $7.72M | $4.88M | $3.66M | $3.34M |
| Total Current Liabilities | $18.11M | $25.33M | $44.17M | $52.43M | $54.06M | $58.22M | $58.58M | $59.14M | $55.38M | $54.69M | $98.16M | $47.92M | $45.21M | $39.05M | $23.81M | $22.51M | $16.69M | $14.51M | $11.90M | $11.95M |
| Long Term Debt | $11.53M | $12.29M | $12.82M | $13.58M | $9.14M | $9.63M | $10.09M | $10.54M | $10.97M | $11.40M | $11.80M | $12.31M | $12.69M | $13.06M | $13.39M | $13.73M | $14.05M | $14.37M | $14.71M | $- |
| Deferred Revenue Non-Current | $- | $- | $2.31M | $2.31M | $3.38M | $14.45M | $22.39M | $27.70M | $31.34M | $39.16M | $48.97M | $57.52M | $64.67M | $73.11M | $41.99M | $46.14M | $4.42M | $5.67M | $6.73M | $7.79M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-11.80M | $-12.31M | $-12.69M | $-13.06M | $-13.39M | $-13.73M | $-14.05M | $-14.37M | $-14.71M | $- |
| Other Non-Current Liabilities | $13.40M | $22.58M | $20.79M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $136.32M |
| Total Non-Current Liabilities | $24.93M | $34.87M | $35.92M | $15.90M | $12.52M | $24.09M | $32.48M | $38.24M | $42.32M | $50.55M | $60.77M | $69.83M | $77.36M | $86.17M | $55.39M | $59.87M | $18.47M | $20.04M | $21.44M | $144.11M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $43.04M | $60.20M | $80.09M | $68.33M | $66.58M | $82.31M | $91.06M | $97.38M | $97.70M | $105.25M | $158.94M | $117.75M | $122.58M | $125.22M | $79.20M | $82.38M | $35.16M | $34.54M | $33.34M | $156.06M |
| Preferred Stock | $8.83M | $6.78M | $5.25M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $142.39M | $157.02M | $166.93M | $- |
| Common Stock | $1.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $1.00K |
| Retained Earnings | $-364.60M | $-362.80M | $-363.86M | $-352.52M | $-334.10M | $-322.46M | $-305.11M | $-284.79M | $-263.24M | $-246.56M | $-229.79M | $-168.07M | $-156.71M | $-143.41M | $-130.72M | $-118.16M | $-103.89M | $-87.99M | $-76.17M | $-62.59M |
| Accumulated Other Comprehensive Income Loss | $1.00K | $5.00K | $- | $-3.00K | $-28.00K | $-56.00K | $-88.00K | $-47.00K | $- | $-2.00K | $-17.00K | $3.00K | $127.00K | $242.00K | $471.00K | $41.00K | $85.00K | $110.00K | $26.00K | $-1.01M |
| Other Total Stockholders Equity | $369.14M | $365.79M | $364.57M | $357.92M | $351.04M | $349.16M | $346.58M | $342.90M | $340.21M | $337.48M | $332.19M | $221.91M | $217.33M | $215.07M | $213.53M | $212.38M | $211.04M | $210.35M | $209.74M | $10.12M |
| Total Stockholders Equity | $4.54M | $3.00M | $715.00K | $5.40M | $16.91M | $26.64M | $41.38M | $58.07M | $76.97M | $90.93M | $102.38M | $53.84M | $60.74M | $71.91M | $83.29M | $94.22M | $107.23M | $122.47M | $133.59M | $-53.48M |
| Total Equity | $4.54M | $3.00M | $715.00K | $5.40M | $16.91M | $26.64M | $41.38M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $47.58M | $63.20M | $80.81M | $73.73M | $83.50M | $108.95M | $132.45M | $155.45M | $174.67M | $196.18M | $261.32M | $171.59M | $183.32M | $197.12M | $162.50M | $176.60M | $142.39M | $157.02M | $166.93M | $102.58M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $47.58M | $63.20M | $80.81M | $73.73M | $83.50M | $108.95M | $132.45M | $155.45M | $174.67M | $196.18M | $261.32M | $171.59M | $183.32M | $197.12M | $162.50M | $176.60M | $142.39M | $157.02M | $166.93M | $102.58M |
| Total Investments | $13.87M | $12.76M | $673.00K | $1.50M | $15.73M | $21.59M | $61.73M | $180.82M | $111.24M | $97.80M | $168.07M | $128.81M | $139.67M | $140.71M | $102.07M | $66.39M | $64.46M | $81.79M | $51.62M | $- |
| Total Debt | $14.50M | $15.17M | $15.61M | $16.01M | $10.97M | $11.40M | $11.80M | $12.19M | $12.56M | $12.94M | $13.28M | $13.52M | $14.05M | $14.37M | $14.66M | $14.94M | $15.04M | $15.23M | $15.28M | $- |
| Net Debt | $-3.23M | $-17.63M | $-45.78M | $-35.61M | $-39.40M | $-57.17M | $-38.94M | $-32.50M | $-30.43M | $-64.48M | $-58.05M | $-7.66M | $-8.60M | $-20.37M | $-21.51M | $-140.19M | $-41.73M | $-118.65M | $-80.64M | $-89.49M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Net Income | $-67.73M | $-116.72M | $-49.91M | $-55.57M | $-27.37M |
| Depreciation and Amortization | $2.36M | $2.19M | $2.08M | $900.00K | $644.00K |
| Deferred Income Tax | $- | $2.37M | $491.00K | $-541.00K | $- |
| Stock Based Compensation | $8.64M | $9.46M | $4.86M | $2.07M | $672.00K |
| Change in Working Capital | $-33.58M | $-19.91M | $33.43M | $49.05M | $-1.08M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $2.05M | $542.00K | $-1.23M | $-1.76M | $2.56M |
| Other Working Capital | $-35.62M | $-20.45M | $34.66M | $50.81M | $-3.63M |
| Other Non Cash Items | $1.13M | $456.00K | $432.00K | $1.20M | $- |
| Net Cash Provided by Operating Activities | $-89.18M | $-122.15M | $-8.62M | $-2.89M | $-27.13M |
| Investments in Property Plant and Equipment | $-347.00K | $-100.00K | $-683.00K | $-3.52M | $-663.00K |
| Acquisitions Net | $-89.74M | $- | $- | $- | $- |
| Purchases of Investments | $-24.43M | $-151.97M | $-202.18M | $-141.82M | $- |
| Sales Maturities of Investments | $114.51M | $186.42M | $139.24M | $76.02M | $- |
| Other Investing Activities | $89.74M | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $89.74M | $34.35M | $-63.63M | $-69.31M | $-663.00K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $5.38M | $110.35M | $3.03M | $70.65M | $89.83M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $6.37M | $111.52M | $4.68M | $71.45M | $88.33M |
| Net Cash Used Provided by Financing Activities | $6.37M | $111.52M | $4.68M | $71.45M | $88.33M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $6.93M | $23.72M | $-67.57M | $-757.00K | $60.54M |
| Cash at End of Period | $52.29M | $45.36M | $21.64M | $89.20M | $89.96M |
| Cash at Beginning of Period | $45.36M | $21.64M | $89.20M | $89.96M | $29.42M |
| Operating Cash Flow | $-89.18M | $-122.15M | $-8.62M | $-2.89M | $-27.13M |
| Capital Expenditure | $-347.00K | $-100.00K | $-683.00K | $-3.52M | $-663.00K |
| Free Cash Flow | $-89.53M | $-122.25M | $-9.30M | $-6.41M | $-27.79M |
Cash Flow Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-1.80M | $1.06M | $-11.34M | $-18.42M | $-11.64M | $-17.35M | $-20.32M | $-21.55M | $-16.68M | $-16.76M | $-61.72M | $-11.36M | $-13.31M | $-12.69M | $-12.55M | $-14.27M | $-15.91M | $-11.82M | $-13.58M | $-9.73M |
| Depreciation and Amortization | $236.00K | $370.00K | $662.00K | $678.00K | $527.00K | $548.00K | $604.00K | $558.00K | $534.00K | $549.00K | $549.00K | $537.00K | $530.00K | $512.00K | $503.00K | $500.00K | $-196.00K | $299.00K | $297.00K | $197.00K |
| Deferred Income Tax | $-180.00K | $2.25M | $- | $- | $- | $- | $- | $515.00K | $686.00K | $594.00K | $574.00K | $236.00K | $125.00K | $70.00K | $60.00K | $-59.00K | $-261.00K | $-176.00K | $-45.00K | $1.07M |
| Stock Based Compensation | $918.00K | $1.06M | $1.13M | $1.49M | $1.78M | $2.52M | $2.84M | $2.65M | $2.34M | $2.34M | $2.14M | $1.33M | $1.50M | $1.18M | $847.00K | $643.00K | $592.00K | $467.00K | $369.00K | $211.00K |
| Change in Working Capital | $-6.69M | $-23.02M | $-10.21M | $-2.35M | $-14.76M | $-7.63M | $-8.83M | $845.00K | $-7.70M | $-53.42M | $40.36M | $-6.03M | $-2.45M | $48.38M | $-6.47M | $46.81M | $4.19M | $-2.19M | $245.00K | $2.88M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $500.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $806.00K |
| Accounts Payables | $368.00K | $-666.00K | $-710.00K | $2.10M | $-178.00K | $-821.00K | $946.00K | $571.00K | $-455.00K | $-644.00K | $1.07M | $-413.00K | $217.00K | $58.00K | $-1.09M | $-1.06M | $179.00K | $-105.00K | $-771.00K | $2.56M |
| Other Working Capital | $-7.05M | $-22.35M | $-9.50M | $-4.46M | $-14.59M | $-6.81M | $-9.78M | $274.00K | $-7.25M | $-52.77M | $39.29M | $-5.62M | $-2.67M | $48.33M | $-5.38M | $47.87M | $4.01M | $-2.09M | $1.02M | $-992.00K |
| Other Non Cash Items | $-9.02M | $3.09M | $464.00K | $213.00K | $146.00K | $310.00K | $465.00K | $152.00K | $144.00K | $135.00K | $25.00K | $120.00K | $110.00K | $104.00K | $98.00K | $92.00K | $348.00K | $474.00K | $288.00K | $-1.07M |
| Net Cash Provided by Operating Activities | $-16.53M | $-15.18M | $-19.29M | $-18.39M | $-23.95M | $-21.60M | $-25.24M | $-16.83M | $-20.68M | $-66.57M | $-18.08M | $-15.17M | $-13.49M | $37.55M | $-17.52M | $33.72M | $-11.24M | $-12.95M | $-12.43M | $-6.44M |
| Investments in Property Plant and Equipment | $-91.00K | $- | $- | $-28.00K | $-266.00K | $-53.00K | $597.00K | $-55.00K | $- | $- | $-45.00K | $-58.00K | $-470.00K | $-150.00K | $-5.00K | $-369.00K | $-1.75M | $-1.32M | $-72.00K | $-157.00K |
| Acquisitions Net | $- | $341.00K | $938.00K | $- | $- | $- | $-597.00K | $- | $- | $- | $- | $- | $- | $- | $- | $835.00K | $- | $- | $- | $- |
| Purchases of Investments | $-2.94M | $-12.71M | $- | $-11.51M | $-12.92M | $-1.00M | $-10.51M | $-17.40M | $-34.10M | $-17.51M | $-82.96M | $-60.10M | $-35.52M | $-60.06M | $-46.50M | $-52.95M | $-6.57M | $-30.72M | $-51.58M | $- |
| Sales Maturities of Investments | $2.00M | $- | $1.50M | $14.28M | $18.83M | $41.03M | $40.37M | $36.14M | $19.98M | $87.20M | $43.10M | $70.60M | $36.32M | $21.13M | $11.19M | $51.05M | $24.14M | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $11.51M | $- | $-597.00K | $597.00K | $- | $- | $- | $- | $- | $- | $- | $- | $-835.00K | $- | $835.00K | $- | $- |
| Net Cash Used for Investing Activities | $-1.03M | $-12.37M | $2.44M | $14.25M | $5.65M | $39.38M | $30.46M | $18.69M | $-14.12M | $69.69M | $-39.90M | $10.45M | $331.00K | $-39.09M | $-35.32M | $-2.27M | $15.81M | $-31.20M | $-51.65M | $-157.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $2.24M | $262.00K | $1.53M | $5.38M | $101.00K | $- | $830.00K | $1.00K | $- | $2.77M | $107.58M | $3.03M | $- | $- | $- | $-1.00K | $-17.00K | $191.00K | $70.47M | $89.83M |
| Common Stock Repurchased | $748.58M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.03M | $-1.04M | $26.62M | $5.39M | $101.00K | $52.00K | $830.00K | $47.00K | $380.00K | $2.95M | $108.14M | $3.24M | $1.07M | $101.00K | $265.00K | $525.00K | $99.00K | $318.00K | $70.51M | $68.24M |
| Net Cash Used Provided by Financing Activities | $2.03M | $-1.04M | $26.62M | $5.39M | $101.00K | $52.00K | $830.00K | $47.00K | $380.00K | $2.95M | $108.14M | $3.24M | $1.07M | $101.00K | $265.00K | $525.00K | $99.00K | $318.00K | $70.51M | $68.24M |
| Effect of Forex Changes on Cash | $1.48B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-15.53M | $-28.59M | $9.77M | $1.25M | $-18.20M | $17.83M | $6.05M | $1.90M | $-34.42M | $6.08M | $50.16M | $-1.48M | $-12.09M | $-1.43M | $-52.57M | $31.97M | $4.67M | $-43.83M | $6.43M | $61.63M |
| Cash at End of Period | $17.94M | $33.47M | $62.06M | $52.29M | $51.04M | $69.24M | $51.41M | $45.36M | $43.46M | $77.88M | $71.80M | $21.64M | $23.12M | $35.20M | $36.63M | $89.20M | $57.23M | $52.56M | $96.39M | $89.96M |
| Cash at Beginning of Period | $33.47M | $62.06M | $52.29M | $51.04M | $69.24M | $51.41M | $45.36M | $43.46M | $77.88M | $71.80M | $21.64M | $23.12M | $35.20M | $36.63M | $89.20M | $57.23M | $52.56M | $96.39M | $89.96M | $28.32M |
| Operating Cash Flow | $-16.53M | $-15.18M | $-19.29M | $-18.39M | $-23.95M | $-21.60M | $-25.24M | $-16.83M | $-20.68M | $-66.57M | $-18.08M | $-15.17M | $-13.49M | $37.55M | $-17.52M | $33.72M | $-11.24M | $-12.95M | $-12.43M | $-6.44M |
| Capital Expenditure | $-91.00K | $- | $- | $-28.00K | $-266.00K | $-53.00K | $597.00K | $-55.00K | $- | $- | $-45.00K | $-58.00K | $-470.00K | $-150.00K | $-5.00K | $-369.00K | $-1.75M | $-1.32M | $-72.00K | $-157.00K |
| Free Cash Flow | $-16.62M | $-15.18M | $-19.29M | $-18.42M | $-24.22M | $-21.66M | $-24.64M | $-16.89M | $-20.68M | $-66.57M | $-18.12M | $-15.22M | $-13.96M | $37.41M | $-17.52M | $33.35M | $-12.99M | $-14.27M | $-12.50M | $-6.60M |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
$23.01
Stock Price
$865.08M
Market Cap
50
Employees
South San Francisco, CA
Location
Revenue (FY 2022)
$31.91M
34.9% YoY
Net Income (FY 2022)
$-67.14M
59.7% YoY
EPS (FY 2022)
$-20.24
60.8% YoY
Free Cash Flow (FY 2022)
$-89.53M
26.8% YoY
Profitability
Gross Margin
90.3%
Net Margin
-210.4%
ROE
-1243.5%
ROA
-91.1%
Valuation
P/E Ratio
-0.36
P/S Ratio
0.75
EV/EBITDA
0.17
Market Cap
$865.08M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-89.18M
27.0% YoY
Free Cash Flow
$-89.53M
26.8% YoY
Balance Sheet Summary
Total Assets
$73.73M
-52.6% YoY
Total Debt
$16.01M
31.3% YoY
Shareholder Equity
$5.40M
-91.0% YoY
Dividend Overview
No Dividend Data
Harpoon Therapeutics, Inc. doesn't currently pay dividends.
Harpoon Therapeutics Dividends
Explore Harpoon Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Harpoon Therapeutics News
Read the latest news about Harpoon Therapeutics, including recent articles, headlines, and updates.
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon's common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. “We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide,” said Dr. Dean Y. Li, pr.
HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Harpoon Therapeutics, Inc. (NasdaqCM: HARP) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Harpoon will receive $23.00 in cash for each share of Harpoon that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.
Shareholder Alert: Ademi LLP investigates whether Harpoon Therapeutics, Inc. has obtained a Fair Price in its transaction with Merck
MILWAUKEE , Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Harpoon (Nasdaq: HARP) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join the https://www.ademilaw.com/case/harpoon-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Harpoon Therapeutics, Inc. (NASDAQ: HARP) to Merck for $23.00 per share in cash is fair to Harpoon shareholders. Halper Sadeh encourages Harpoon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Harpoon and its b.
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. “At Merck, we continue to enhance our oncology pipeline through strategic acquisitions that compl.
Merck close to acquiring cancer specialist Harpoon Therapeutics
Merck & Co Inc (NYSE:MRK) is close to acquiring Harpoon Therapeutics Inc, a cancer drug developer, for about $700 million to bolster its oncology portfolio. The proposed deal, which could value Harpoon at $23 per share, aligns with Merck's strategy to seek new growth opportunities as its top-selling cancer drug Keytruda faces future pricing pressures.
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) being held in San Francisco, CA and virtually on January 25-27, 2024. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's own immune cells to kill tumor cells.
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy
Should You Buy Harpoon Therapeutics, Inc. (HARP) After Golden Cross?
Harpoon Therapeutics, Inc. (HARP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, HARP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Wall Street Analysts Believe Harpoon Therapeutics, Inc. (HARP) Could Rally 40.5%: Here's is How to Trade
The consensus price target hints at a 40.5% upside potential for Harpoon Therapeutics, Inc. (HARP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Harpoon: HPN328 Data In 1st Half Of 2024 Makes This A Must Watch
HPN328 is being advanced in a phase 1/2 study for the treatment of patients with neuroendocrine tumors; Promising interim data was released at ESMO 2023 medical conference. Updated data from the phase 1/2 study, using HPN328 for the treatment of patients with neuroendocrine tumors, is expected to be released in the 1st half of 2024. The global neuroendocrine tumors treatment market revenue is expected to increase to $6.33 billion by 2030.
Fast-paced Momentum Stock Harpoon Therapeutics, Inc. (HARP) Is Still Trading at a Bargain
Harpoon Therapeutics, Inc. (HARP) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Wall Street Analysts See a 92.31% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?
The mean of analysts' price targets for Harpoon Therapeutics, Inc. (HARP) points to a 92.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung cancer (SCLC) and other neuroendocrine tumor types presented at ESMO 2023 HPN328 Phase 2 monotherapy dose(s) selection on track for year-end 2023 for discussion with regulators in 1H 2024 Data update of ongoing HPN328 Phase 1/2 trial expected in 1H 2024 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The oral presentation will take place at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego.
Harpoon Therapeutics stock soars on ‘promising' lung cancer drug results
Harpoon Therapeutics Inc shares surged as much as 40% in pre-market trading on Monday after the clinical-stage immunotherapy company announced that its lung cancer drug (HPN328) showed "promising" antitumor activity and tolerability profile in a Phase 1/2 clinical trial. Harpoon said the preliminary response data for evaluable patients treated in one milligram priming dose cohorts showed confirmed response rate of 35% across all tumor types.
Harpoon Therapeutics Announces Up to $150 Million Private Placement
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a securities purchase agreement for a private placement in public equity (“PIPE”) financing that is expected to result in upfront gross proceeds of approximately $100 million, with up to an additional approximately $50 million of gross proceeds upon cash exercise of warrants, before deducting placement agent fees and offering expenses. The PIPE financing was led by a leading biotechnology investor associated with one of the largest alternative asset managers, with participation from new and existing investors including Soleus Capital, Commodore Capital, New Leaf Venture Partners, Cormorant Asset Management, RA Capital Management, Invus, Surveyor Capital (a Citadel company), K2 HealthVentures, Ally Bridge Group, Lion Point Capital, and a large mutual fund.
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types in a poster at the European Society of Medical Oncology Congress (ESMO) 2023. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's own immune cells to kill tumor cells.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for HARP.